President Donald Trump unveiled a new initiative aimed at making prescription medications more affordable for Americans.
The program, called TrumpRx, is a collaboration with Pfizer that allows patients to purchase select medications directly through a government-backed platform at discounted rates negotiated with the company.
The White House officially unveiled TrumpRx alongside Pfizer CEO Albert Bourla during a briefing on Tuesday.
TrumpRx is designed to bypass traditional intermediaries, giving consumers the option to pay cash for select prescriptions at prices set by the federal government.
The initiative builds on the administration’s broader effort to increase transparency in drug pricing and expand direct-to-consumer access, The Post Millennial reports.
During the briefing, President Trump emphasized the burden high drug prices have placed on U.S. consumers.
“For many years, Americans have paid the highest prices anywhere in the world for prescription drugs,” he said. “Ten times, 13 times, 15 times more than other countries for the exact same product.”
“The United States accounts for just 4% of global consumers, yet pharmaceutical companies earn 75% of their profits here,” he added.
Trump also outlined Pfizer’s commitment through the program.
“Today Pfizer is committing to offer all of their prescription medications to Medicaid at most-favored-nation prices,” he said. “This will significantly reduce Medicaid costs. In addition, some of their most popular drugs will be available to all consumers at discounts ranging from 50 to 100%.”
The president called the move a major step toward easing financial strain for low-income patients.
Health and Human Services Secretary Robert F. Kennedy Jr. praised the plan, noting that past administrations had struggled to achieve such results.
“Democrats and Republicans have wanted this for decades, but no president had succeeded until President Trump pressed pharmaceutical companies to act,” Kennedy said. “His persistence made it happen.”
Prior to Trump’s announcement, White House spokesperson Kush Desai highlighted the president’s hands-on approach.
“President Trump is doing more to lower healthcare costs than anyone else in Washington, D.C.” he told the Washington Examiner.
He added that the president “is leveraging the power of the federal government to drastically cut drug prices for everyday Americans.”
TrumpRx also aligns with the administration’s Most Favored Nation policy, which aims to match U.S. drug prices with those in countries that negotiate prices through socialized healthcare systems.
The administration has warned that companies failing to produce medications domestically could face tariffs of up to 100 percent, while participation in TrumpRx allows firms like Pfizer to meet pricing requirements and avoid penalties.
Just the News highlighted the urgency of this program, underscored by the latest polling data.
A May survey from the Napolitan News Service found that 56 percent of Americans cite corporate greed as the main driver of high drug costs, while only 20 percent point to government regulation.
Healthcare expenses consistently rank among the top voter concerns nationwide.
The platform is expected to provide a transparent, direct-to-consumer option for both insured and uninsured Americans, offering a practical solution to long-standing prescription drug pricing challenges.
WATCH:
